Overview
Magne Stridh practices practicing medicine in Lund, Sweden.
Their clinical expertise encompasses Squamous Cell Skin Carcinoma, Angiosarcoma, and Basal Cell Skin Cancer.
They are actively involved in clinical research, co-authoring 8 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Magne T. Stridh
Is Magne T. Stridh a top-rated expert for Squamous Cell Skin Carcinoma?
MediFind is an objective health platform that identifies experts based on real-world data. Magne T. Stridh is classified as an Experienced expert for Squamous Cell Skin Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Magne T. Stridh participate in research or clinical trials?
Yes. Magne T. Stridh has published 8 articles and abstracts on conditions like Squamous Cell Skin Carcinoma. You can view a list of Magne T. Stridh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- AngiosarcomaStridh isExperienced. Learn about Angiosarcoma.
- Basal Cell Skin CancerStridh isExperienced. Learn about Basal Cell Skin Cancer.
- Squamous Cell Skin CarcinomaStridh isExperienced. Learn about Squamous Cell Skin Carcinoma.